Research librarySecretagogues and GHRH analogues
IGF-1 LR3: Structure and Binding-Protein Biology
For laboratory research use only. The compounds discussed here are sold strictly for in vitro research. They are not drugs, supplements or cosmetics and are not for human or animal use. This article summarizes published literature for reference and is not medical or usage advice.
Start with the name, because it does most of the explaining. IGF-1 LR3, where “LR3” means Long Arg3. You take insulin-like growth factor 1, bolt 13 residues onto the N-terminus, then trade the glutamate at position 3 for an arginine. Two edits, both small. And yet they rewire how the thing deals with its binding proteins, which turns out to be what everyone cares about. So: what it is, where it came from, what the papers found. Links throughout.
Key findings
- IGF-1 LR3 traces to the “Long [Arg3]-IGF-I” analogue first made in E. coli and written up in 1992 [1].
- The Arg3 swap drops its affinity for IGF binding proteins (IGFBPs), the carriers that normally lock IGF-I up [1][2].
- In pigs and marmosets, IGF-I variants that bind IGFBPs poorly acted more potently and for longer than native IGF-I [2].
- Native IGF-I is a 70 residue, three disulfide protein, and its solution structure has been mapped by NMR [3][4].
- Add the extension and the molecular weight climbs to roughly 9,100 to 9,200 Da, up from the native peptide’s ~7,650 Da.
What IGF-1 LR3 is
So what is it, physically? A recombinant analogue of human insulin-like growth factor 1. The native version is one chain, 70 amino acids, held together by three disulfide bonds, and it’s a structural relative of proinsulin [3]. LR3 keeps that core intact and adds the two changes above: the 13 residue extension, and arginine where glutamate used to sit at position 3. That swap is the “Arg3” part. With the extension on, you’re at roughly 9,100 to 9,200 Da, well north of the native protein.
None of this was guesswork. The analogue came out of a deliberate protein-engineering program, and that pedigree is why its literature reads cleaner than the usual research-peptide fog.
Where the molecule came from
Trace the Long [Arg3]-IGF-I sequence back and you land on a 1992 paper from Francis and colleagues, who cooked up a small family of IGF-I fusion analogues in E. coli [1]. Three peptides fell out: the authentic sequence, a glycine-at-3 version (Long [Gly3]-IGF-I), and an arginine-at-3 version (Long [Arg3]-IGF-I) [1]. That “Long” prefix? It’s just the N-terminal extension left behind by the expression tag. Why build the whole set? To split apart how much of IGF-I’s punch comes from receptor binding versus binding-protein binding [1]. So the IGF-1 LR3 you read about today is, essentially, that Long [Arg3] construct.
The binding-protein story
Here’s the mechanistic heart of it. In the blood, native IGF-I almost never floats around free. A family of IGF binding proteins (IGFBPs) grabs it and decides how much is available moment to moment. The position-3 substitution weakens IGF-1 LR3’s grip on those IGFBPs [1][2]. Weaker binding-protein affinity, more of the molecule left unbound. Simple as that.
Tomas and colleagues tested exactly this. In pigs and marmoset monkeys, IGF-I variants that bound IGFBPs poorly turned out more potent and longer-acting than native IGF-I [2]. That’s the cleanest in vivo evidence for why the Arg3 edit matters. Notice what it isn’t doing: it’s not really changing what IGF-I does at the receptor, it’s changing how long and how freely the molecule circulates. Older write-ups just asserted the “longer half-life” line with nothing behind it, so weigh the mechanism, not the marketing.
Why researchers engineered it at all
Worth asking why anyone modified IGF-I in the first place. Native IGF-I is a pain to work with. It’s barely ever free in circulation, and in the lab it clumps, which wrecks both structural studies and clean concentration-response work. The Francis analogues were partly meant as better reagents: molecules you could actually make in bulk that behaved more predictably around binding proteins [1]. The Arg3 edit was one lever in a set that also included the Gly3 variant, and comparing them is what let the team peel apart receptor effects from binding-protein effects [1]. That’s a far better experimental pedigree than most research peptides can point to.
Reading the half-life claim carefully
Nearly every description of IGF-1 LR3 opens with “longer half-life,” so let’s be precise about it. The extra circulating time isn’t about the receptor. It comes from dodging the IGFBPs that would otherwise hold native IGF-I and release it on their own clock [1][2]. The half-life difference is a binding-protein thing, full stop. Tomas and colleagues made it concrete by showing the poorly-IGFBP-binding variants acted both harder and longer in two species [2]. See a specific half-life figure quoted with no model attached? Treat it as unverified, because those numbers swing hard with species and assay.
A word on “more potent,” too. In the Tomas work it meant a bigger, longer response per unit of peptide against native IGF-I, measured in whole animals rather than one cell line [2]. That distinction matters, because for a molecule ruled by carrier proteins, in vitro and in vivo numbers can split wide apart. The whole point of the LR3 design is to nudge those two readouts closer by taking the binding proteins partway out of the picture [1][2].
Structure and how it’s characterized
The native IGF-I fold has been studied to death by NMR, though the protein is famously uncooperative: it aggregates at the concentrations NMR wants and throws broad peaks [4]. Kuang and colleagues sorted out chemical shift assignments near physiological pH to get around that [4], and earlier work solved a full three-dimensional solution structure of an IGF-I disulfide isomer [3]. The bench takeaway for IGF-1 LR3 is that these molecules carry three disulfide bonds and can misfold or clump, so correct folding is something a real analysis has to confirm, not just the mass. Identity and purity get nailed down by reversed-phase HPLC and mass spectrometry, with the ~9,100 Da mass as the anchor.
IGF-1 LR3 versus native IGF-I and DES
Nobody really considers IGF-1 LR3 by itself. The two usual comparisons are native IGF-I and IGF-1 DES, another engineered variant that chops off the first three N-terminal residues. DES and LR3 share the same logic: shed IGFBP affinity so more of the molecule stays free [2]. They just get there by opposite moves, one a deletion and one an extension-plus-swap. For the head-to-head, see our IGF-1 LR3 versus DES comparison.
| Molecule | Key modification | IGFBP affinity | Approx. molecular weight |
|---|---|---|---|
| Native IGF-I | None (70 residues) | High [1] | ~7,650 Da |
| IGF-1 LR3 | N-terminal +13 residues, Arg at position 3 | Reduced [1][2] | ~9,100 to 9,200 Da |
| IGF-1 DES | First 3 N-terminal residues removed | Reduced [2] | ~7,370 Da |
Frequently asked questions
What does LR3 stand for in IGF-1 LR3?
Long Arg3: a long N-terminal extension plus arginine swapped in at position 3 of the IGF-I sequence [1].
Why does the Arg3 substitution matter?
It weakens the molecule’s grip on IGF binding proteins, and in animal studies that tracked with more potent, longer-acting results than native IGF-I [1][2].
How big is IGF-1 LR3 compared to native IGF-I?
Roughly 9,100 to 9,200 Da against about 7,650 Da for the 70 residue native protein, the gap coming from the 13 residue extension [1][3].
References
- Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 1992. PMID 1378742
- Tomas FM, Walton PE, Dunshea FR, Ballard FJ. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. J Endocrinol. 1997. PMID 9415072
- Sato A, Koyama S, Yamada H, et al. Three-dimensional solution structure of a disulfide bond isomer of the human insulin-like growth factor-I. J Pept Res. 2000. PMID 11083061
- Kuang Z, Yao S, McNeil KA, et al. Insulin-like growth factor-I (IGF-I): solution properties and NMR chemical shift assignments near physiological pH. Growth Horm IGF Res. 2009. PMID 19056307
USA-made peptides, third-party tested every batch, with the COA published for each lot.